---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016871"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:22:22.357579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech regains Nasdaq compliance; Sentynl takes over CUTX-101 development

## Summary
- Nasdaq notified Fortress on Oct 24, 2023 of compliance with $1.00 bid price requirement; listing matter closed.
- Sentynl elected Approval Deadline Transfer for CUTX-101 after NDA not approved by Sep 30, 2023; closing expected Nov 2023.
- Cyprium retains up to $133.5M in milestones, tiered royalties (3%–12.5%), and any priority review voucher.
- Transfer expected to reduce Cyprium's development spending on CUTX-101.

## SEC filing metadata
- accession: 0001558370-23-016871
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837023016871/0001558370-23-016871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837023016871/fbio-20231024x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016871
- JSON: https://secwatch.observer/filing/0001558370-23-016871.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.